Sponsored Content

Probing the Source of an Unstable Impurity and Controlling Its Formation at Release

APT-76 is an anti-neoplastic agent and currently being developed

Company Logo

Released By Adare Pharma Solutions

APT-76 is an anti-neoplastic agent and currently being developed as an extended-release formulation (enteric coating) for an ongoing early Phase 1 clinical trial. The finished drug product is a capsule filled with mini tablets. Two major issues related to impurities were encountered during the formulation and analytical stages:

Fill out the form to download the article >>>

Download Sponsored Content Now

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters